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ABSTRACT
Background In patients with suspected angina
pectoris, CT coronary angiography (CTCA) clariﬁes the
diagnosis, directs appropriate investigations and
therapies, and reduces clinical events. The effect on
patient symptoms is currently unknown.
Methods In a prospective open-label parallel group
multicentre randomised controlled trial, 4146 patients
with suspected angina due to coronary heart disease
were randomised 1:1 to receive standard care or
standard care plus CTCA. Symptoms and quality of life
were assessed over 6 months using the Seattle Angina
Questionnaire and Short Form 12.
Results Baseline scores indicated mild physical
limitation (74±0.4), moderate angina stability (44±0.4),
modest angina frequency (68±0.4), excellent treatment
satisfaction (92±0.2) and moderate impairment of
quality of life (55±0.3). Compared with standard care
alone, CTCA was associated with less marked
improvements in physical limitation (difference −1.74
(95% CIs, −3.34 to −0.14), p=0.0329), angina
frequency (difference −1.55 (−2.85 to −0.25),
p=0.0198) and quality of life (difference −3.48
(−4.95 to −2.01), p<0.0001) at 6 months. For patients
undergoing CTCA, improvements in symptoms were
greatest in those diagnosed with normal coronary
arteries or who had their preventative therapy
discontinued, and least in those with moderate
non-obstructive disease or had a new prescription of
preventative therapy (p<0.001 for all).
Conclusions While improving diagnosis, treatment
and outcome, CTCA is associated with a small
attenuation of the improvements in symptoms and
quality of life due to the detection of moderate
non-obstructive coronary artery disease.
Trial registration number: NCT01149590.
INTRODUCTION
We have reported the primary ﬁndings of the
Scottish COmputed Tomography of the HEART
(SCOT-HEART) trial1 and demonstrated that,
when used in addition to standard care, CT coron-
ary angiography (CTCA) clariﬁed the diagnosis of
angina pectoris due to coronary heart disease. This
was associated with better selection of patients for
invasive coronary angiography, more appropriate
changes in therapy and a halving in the rates of
fatal and non-fatal myocardial infarction.2
In the SCOT-HEART trial,1 one-third of patients
were diagnosed with angina pectoris due to coron-
ary heart disease. For the attending clinician,
CTCA clariﬁed the diagnosis of both coronary
heart disease and angina pectoris due to coronary
heart disease. However, CTCA had divergent
effects on the frequency of these diagnoses with an
increased rate in the diagnosis of coronary heart
disease and an apparent reduction in the diagnosis
of angina pectoris due to coronary heart disease.
This was principally attributable to an increase in
the diagnosis of non-obstructive coronary heart
disease by CTCA.
There is substantial anxiety about the potential
for, and consequences of, coronary heart disease in
patients presenting with undifferentiated chest
pain.3 Patients are looking for clear reassurance as
well as a resolution to their symptoms. For the
patients, the critical question is whether CTCA will
help their symptoms and improve their future prog-
nosis. Here, we assessed how CTCA affected the
changes in patients’ symptoms and quality of life at
6 weeks and 6 months after their attendance at the
cardiology clinic.
METHODS
Study design
The SCOT-HEART study was a prospective open-
label parallel group multicentre randomised con-
trolled trial that assessed the role of CTCA in
patients with suspected angina due to coronary
heart disease who attended a cardiology clinic. The
study design has previously been described4 and
the primary ﬁndings published.12
Participants
Participants were recruited from a dedicated cardi-
ology chest pain clinic where they were referred
with suspected angina due to coronary heart
disease. A total of 4146 patients aged 18–75 were
recruited as described previously.1 Participants were
randomised 1:1 to standard care or standard care
plus ≥64-slice CTCA using a web-based randomisa-
tion system. Standard of care included stress testing
according to established local clinical protocols.
  995Williams MC, et al. Heart 2017;103:995–1001. doi:10.1136/heartjnl-2016-310129
Coronary artery disease
To cite: Williams MC, 
Hunter A, Shah A, et al. Heart 
2017;103:995–1001.
 ► Additional material is 
published online only. To view 
please visit the journal online 
(http://dx.doi.org/10.1136/
heartjnl-2016-310129).
For numbered affiliations see 
end of article.
Correspondence to
Professor David Newby, 
University/BHF Centre for 
Cardiovascular Science, 
Chancellor’s Building, SU314, 
49 Little France Crescent, 
Edinburgh EH16 4SA, UK; 
d.e.newby@ed.ac.uk
Received 8 June 2016
Revised 1 August 2016
Accepted 15 August 2016
Published Online First 
28 February 2017
 ► http://dx.doi.org/10.1136/
heartjnl-2016-310473
 o
n
 10 O
ctober 2018 by guest. Protected by copyright.
http://heart.bmj.com/
H
eart: first published as 10.1136/heartjnl-2016-310129 on 28 February 2017. Downloaded from 
Patient and public involvement
Patient and public involvement was incorporated throughout
the trial development, conduct and completion. At study design
stage, we assessed feasibility and received feedback on the
potential acceptability of patient participation in the trial.
During trial conduct, lay representatives contributed to the
membership of the Trial Steering Committee. A lay member
(EC) contributed to this article and is a coauthor.
CT coronary angiography
CTCA images were assessed by at least two trained observers
with excellent reproducibility.5 The overall results of the scan
were deﬁned as normal (<10% cross-sectional luminal stenosis),
mild (10–50%) or moderate (50–70%) non-obstructive or
obstructive (≥70% or >50% in the left main stem) coronary
artery disease.
Seattle Angina Questionnaire and Short Form 12
Angina symptoms were assessed with a self-administered UK
version of the Seattle Angina Questionnaire.6 This questionnaire
measures ﬁve clinically important domains of physical limitation,
angina stability, angina frequency, treatment satisfaction and
quality of life. Scores are expressed on a 0–100 scale with higher
scores denoting better outcomes. It has been validated in patients
with, or being assessed for, coronary heart disease and is respon-
sive to therapeutic interventions.6 The questionnaire was per-
formed at the baseline clinic attendance and then at 6 weeks and
6 months by post. For non-responders, telephone follow-up was
performed where possible. To further assess and compare quality
of life and health measures, participants were also asked to com-
plete 12-item Short Form SF-12v2 Health Survey.7 This is a stan-
dardised instrument that measures eight health domains:
physical functioning, role limitations due to physical health,
bodily pain, general health, vitality (energy/fatigue), social func-
tioning, role limitations due to emotional health and mental
health (psychological distress and psychological well-being).
Statistical analysis
Data are presented as mean±SE or mean differences with 95%
CIs. Response rates to the Seattle Angina Questionnaires were
compared between treatment arms with χ2 tests at each time
point. Changes in the Seattle Angina Questionnaire and Short
Form 12 were compared between treatment arms using t-tests.
In patients allocated to CTCA, changes over time were
compared according to the changes in the diagnosis of coronary
heart disease and angina pectoris due to coronary heart disease
using analysis of covariance. This was adjusted for the baseline
score, centre and the minimisation variables (age, sex, body
mass index, diabetes mellitus, atrial ﬁbrillation, history of coron-
ary heart disease and baseline diagnosis of angina pectoris due
to coronary heart disease). We then performed univariable
mixed models to investigate how symptom-related variables
could help explain the changes in Seattle Angina Questionnaire
scores at 6 months. All these analyses were adjusted for the base-
line score. Finally, we extended the univariate model by building
multivariable mixed models for each score using a stepwise
approach. Statistical analysis was performed using SAS V.9.4.
Statistical signiﬁcance was deﬁned as a two-sided p<0.05.
RESULTS
Of the 4146 patients recruited to the trial, 1432 (34.5%)
patients were diagnosed with angina due to coronary heart
disease after 6 weeks of follow-up. Seattle Angina
Questionnaires were completed in 4142 (99.9%) at baseline,
3427 (82.7%) at 6 weeks and 3035 (73.2%) at 6 months.
Although rates of completion were identical at baseline (99.9%
for both), those assigned to CTCA were slightly more likely to
complete the questionnaire than those allocated to standard care
alone at both 6 weeks (84.7% vs 80.7%, p=0.0007) and
6 months (75.3% vs 71.1%, p=0.0018).
Baseline scores across the ﬁve domains of the Seattle Angina
Questionnaire indicated mild physical limitation (74±0.4),
moderate angina stability (44±0.4), modest angina frequency
(68±0.4), excellent treatment satisfaction (92±0.2) and moder-
ate impairment of quality of life (55±0.3). These domains were
similar across the two trial groups at baseline (see online
supplementary table 1).
Changes in symptoms during follow-up
In general, symptoms improved across both study groups during
follow-up (table 1) with the greatest improvements seen in
angina frequency (p<0.001) and quality of life (p<0.001; see
online supplementary table 1). There was little improvement in
physical limitation or treatment satisfaction, perhaps reﬂecting
the mild physical limitation and excellent treatment satisfaction
seen at baseline.
Comparisons of the symptomatic improvement between the
two trial groups demonstrated few early (6 weeks) differences,
Table 1 Changes from baseline in Seattle Angina Questionnaire after 6 weeks and 6 months in patients randomised to standard care plus CT
coronary angiography (CTCA) and standard care alone
All patients Standard care+CTCA Standard care Difference (95% CIs) p Value (for difference)
Change at 6 weeks n=3427 n=1755 n=1672
Physical limitation −0.3±0.4 (2076) −0.5±0.5 (1082) −0.0±0.5 (994) −0.72 (−2.08 to 0.63) 0.2957
Angina stability 16.3±0.6 (3190) 16.7±0.9 (1637) 15.8±0.9 (1553) 1.03 (−0.61 to 2.68) 0.2184
Angina frequency 11.5±0.4 (3264) 11.2±0.6 (1684) 11.8±0.6 (1580) −0.84 (−2.20 to 0.54) 0.2277
Treatment satisfaction −7.0±0.3 (3247) −7.0±0.4 (1675) −7.0±17.1 (1572) 0.03 (−1.07 to 1.14) 0.9525
Quality of life 9.3±0.4 (3261) 8.7±0.5 (1681) 9.9±0.6 (1580) −1.31 (−2.66 to 0.05) 0.0585
Change at 6 months n=3035 n=1562 n=1473
Physical limitation 2.3±0.4 (1814) 1.6±0.6 (937) 3.0±0.6 (877) −1.74 (−3.34 to −0.14) 0.0329
Angina stability 13.0±0.6 (2833) 13.4±0.9 (1462) 12.5±0.9 (1371) 1.27 (−0.27 to 2.80) 0.1059
Angina frequency 18.7±0.4 (2895) 18.3±0.6 (1498) 19.2±0.6 (1397) −1.55 (−2.85 to −0.25) 0.0198
Treatment satisfaction −4.7±0.3 (2872) −5.0±0.4 (1485) −4.3±0.4 (1387) −0.97 (−2.14 to 0.21) 0.1060
Quality of life 17.0±0.4 (2865) 15.5±0.6 (1484) 18.6±0.6 (1381) −3.48 (−4.95 to −2.01) <0.0001
Mean±SE (n).
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but by 6 months, improvements in physical limitation, angina
frequency and especially quality of life were less marked in
those assigned to CTCA (table 1). These differences did not
reﬂect bias in non-responders (see online supplementary table
2), were generally small in magnitude (<4%) but were also con-
sistently seen in the Short Form 12 responses (table 2).
Responder analysis suggested that CTCA was associated with
more patients experiencing an improvement in the stability of
their symptoms at 6 weeks and frequency of their symptoms at
6 months (see online supplementary table 3).
Inﬂuence of the change in diagnosis
Between the initial clinic consultation and 6 weeks, the diagno-
sis of coronary heart disease was changed in 28% of patients
who underwent CTCA compared with 1% of those who
received standard care alone (p<0.001), and the diagnosis of
angina due to coronary heart disease changed in 23% and 1%
(p<0.001), respectively. The change in the diagnosis of coron-
ary heart disease was associated with differing responses to the
changes in symptoms (table 3). In general, improvements in
symptoms of physical limitation, angina frequency and quality
of life were reduced when a new diagnosis of angina pectoris
due to coronary heart disease was made. Similar ﬁndings were
observed for changes to the diagnosis of coronary heart disease
(table 4).
Determinants of symptomatic change
In univariable analyses adjusted for baseline scores (table 5), the
main predictor of symptomatic improvement in patients under-
going CTCA was the baseline score: those with the lowest score
made the most improvement. However, there were other deter-
minants that predicted improvements in symptoms. For both
physical limitation and angina stability, moderate (50–70% sten-
osis) non-obstructive disease was the least favourable and was
associated with deteriorating (physical limitation, −4±1.3) or
lower gains (angina stability, 10±1.4) than patients with normal
(6±1.0 and 15±1.0, respectively), mild non-obstructive (1±1.2
and 15±1.3) or obstructive coronary artery disease (2±1.7 and
16±1.7 for single-vessel disease).
In multivariate analyses, improvements in angina frequency
were predicted by the change in diagnosis of coronary heart
disease (p=0.0498). Where a positive baseline diagnosis of
Table 2 Medical outcomes study Short Form 12 (SF-12)
Standard care+CTCA Standard care Difference (95% CIs) p Value (for difference)
SF-12 physical summary
Baseline 44.2±0.2 (1838) 44.0±0.2 (1829) 0.1 (−0.5 to 0.8) 0.70
6 weeks 44.3±0.3 (1649) 44.5±0.3 (1562) −0.2 (−0.9 to 0.6) 0.66
6 months 45.0±0.3 (1566) 46.0±0.3 (1478) −1.0 (−1.8 to −0.2) 0.01
SF-12 mental summary
Baseline 46.1±0.3 (1838) 46.7±0.3 (1829) −0.6 (−1 3 to 0.2) 0.12
6 weeks 47.2±0.3 (1649) 47.0±0.3 (1562) 0.2 (−0.6 to 1 0) 0.57
6 months 47.8±0.3 (1566) 48.6±0.3 (1478) −0.8 (−1 6 to −0.0) 0.05
SF-6D utility index
Baseline 0.70±0.003 (1882) 0.71±0.003 (1871) −0.01 (−0.01 to 0.00) 0.24
6 weeks 0.72±0.003 (1678) 0.72±0.004 (1591) 0.00 (−0.01 to 0.01) 0.94
6 months 0.73±0.004 (1596) 0.74±0.004 (1505) −0.01 (−0.02 to 0.00) 0.05
Mean±SE (n).
SF-12 physical summary, SF-12 mental summary and SF-6D utility index are subsections of the SF-12 questionnaire.
CTCA, CT coronary angiography.
Table 3 Changes in Seattle Angina Questionnaire after 6 weeks and 6 months according to how the diagnosis of angina pectoris due to
coronary heart disease changed in patients allocated to CT coronary angiography
Diagnosis of angina pectoris due to CHD refuted New diagnosis of angina pectoris due to CHD Unchanged diagnosis p Value*
Total patients (n) 310 171 1588
Change at 6 weeks (n) 277 158 1320
Physical limitation −2.4±1.3 (166) −3.3±1.3 (100) 0.21±0.6 (816) 0.0053
Angina stability 20.4±2.0 (261) 8.9±2.9 (146) 16.8±1.0 (1230) 0.4434
Angina frequency 7.9±1.6 (266) 7.2±1.8 (152) 12.4±0.6 (1266) <0.0001
Treatment satisfaction −7.8±1.0 (264) −7.9±1.4 (150) −6.7±0.5 (1261) 0.4938
Quality of life 9.7±1.5 (261) 4.1±1.6 (151) 9.0±0.6 (1269) 0.0137
Change at 6 months (n) 252 139 1171
Physical limitation 1.9±1.6 (158) −3.5±2.0 (84) 2.1±0.7 (695) 0.0121
Angina stability 18.1±2.0 (242) 7.8±3.3 (128) 13.0±1.1 (1092) 0.8572
Angina frequency 15.8±1.6 (245) 13.4±2.2 (134) 19.5±0.7 (1119) <0.0001
Treatment satisfaction −6.8±1.3 (238) −7.3±1.7 (131) −4.4±0.5 (1116) 0.0510
Quality of life 15.8±1.6 (237) 10.4±2.0 (132) 16.0±0.7 (1115) 0.0060
Mean±SE (n).
Changes in diagnosis reflect those recorded by the attending clinician at 6 weeks postclinic attendance.
*Analysis of variance across the three groups.
CHD, coronary heart disease.
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Table 4 Changes in Seattle Angina Questionnaire after 6 weeks and 6 months according to how the diagnosis of coronary heart disease
changed in patients allocated to CT coronary angiography
Diagnosis of CHD refuted New diagnosis of CHD Unchanged diagnosis p Value
Total patients (n) 423 166 1480
Change at 6 weeks (n) 376 155 1224
Physical limitation 0.3±1.2 (226) −2.0±1.8 (101) −0.6±0.6 (755) 0.8198
Angina stability 17.8±1.7 (345) 7.0±3.1 (147) 17.6±1.1 (1145) 0.1171
Angina frequency 11.3±1.4 (359) 8.1±1.7 (151) 11.6±0.7 (1174) 0.4520
Treatment satisfaction −6.6±0.9 (355) −8.6±1.4 (148) −6.9±0.5 (1172) 0.6693
Quality of life 11.3±1.2 (354) 4.5±1.8 (151) 8.4±0.6 (1176) 0.0819
Change at 6 months (n) 341 137 1084
Physical limitation 3.1±1.4 (206) −3.2±2.0 (81) 1.7±0.7 (650) 0.1036
Angina stability 16.3±1.8 (318) 6.4±3.5 (125) 13.4±1.1 (1019) 0.6374
Angina frequency 18.6±1.5 (330) 10.3±2.1 (129) 19.3±0.7 (1039) 0.0006
Treatment satisfaction −5.0±1.1 (321) −8.3±1.5 (127) −4.6±0.5 (1037) 0.1576
Quality of life 18.0±1.3 (321) 8.6±2.1 (129) 15.6±0.7 (1034) 0.0164
Mean±SE (n).
Changes in diagnosis reflect those recorded by the attending clinician at 6 weeks postclinic attendance.
CHD, coronary heart disease.
Table 5 Univariable mixed models to investigate how symptom-related variables could help explain the changes in Seattle Angina
Questionnaire scores at 6 months
Physical limitation Angina stability Angina frequency Treatment satisfaction Quality of life
Baseline score p<0.0001 p<0.0001 p<0.0001 p<0.0001 p<0.0001
Age (years) p=0.0131 p=0.0743 p=0.3676 p=0.0006 p=0.6478
18–59 2.4±0.8 14.5±0.8 – −6.1±0.6 –
60–75 0.7±0.9 12.3±0.8 – −3.9±0.6 –
Gender p=0.0839 p=0.0546 p=0.5861 p=0.2014 p=0.1543
Female 0.4±0.9 14.7±0.9 – – 16.4±0.8
Male 2.4±0.7 12.5±0.7 – – 14.8±0.7
History of coronary heart disease p=0.0204 p=0.0142 p=0.1495 p=0.6387 p=0.0010
Yes −2.3±1.8 9.3±1.8 16.3±1.5 – 10.2±1.7
No 2.1±0.6 13.9±0.6 18.6±0.5 – 16.1±0.6
Exercise ECG p=0.0410 p=0.6896 p=0.0007 p=0.1514 p=0.0104
Normal 2.1±0.8 – 19.9±0.6 −4.2±0.6 16.7±0.7
Inconclusive −0.7±1.6 – 15.1±1.3 −5.5±1.2 12.9±1.5
Abnormal 4.5±1.5 – 15.6±1.3 −5.6±1.1 15.4±1.4
Not performed −0.9±1.6 – 17.2±1.2 −6.9±1.1 11.9±1.5
CTCA-defined coronary heart disease p<0.0001 p=0.0167 p<0.0001 p=0.0907 p<0.0001
Normal (<10%) 5.9±1.0 14.6±1.0 21.8±0.8 −3.9±0.8 20.1±0.9
Mild non-obstructive (10–50%) 0.9±1.2 15.4±1.3 18.3±1.1 −4.5±.09 15.0±1.2
Moderate non-obstructive (50–70%) −4.3±1.3 9.5±1.4 14.1±1.2 −7.5±1.0 10.7±1.3
Single-vessel disease 1.8±1.7 16.1±1.7 16.4±1.4 −4.7±1.3 14.5±1.6
Two-vessel disease 0.7±2.2 13.4±2.1 17.4±1.8 −2.9±1.6 14.0±2.0
Three-vessel disease 1.4±2.1 12.4±2.2 15.8±1.8 −5.5±1.6 11.2±2.0
Coronary revascularisation* p=0.1164 p=0.1316 p=0.4093 p=0.0437 p=0.8591
Yes 4.3±1.8 15.8±1.7 – −2.5±1.3 –
No 1.3±0.6 13.1±0.6 – −5.3±0.4 –
Preventative therapy p=0.0066 p=0.8253 p=0.1100 p=0.0383 p<0.0001
Cancelled 7.1±2.9 – 23.0±2.4 −1.6±2.2 25.9±2.7
New therapy initiated −2.0±1.5 – 15.7±1.2 −7.14±1.1 11.7±1.4
No change 2.0±0.6 – 18.6±0.5 −4.8±0.5 15.7±0.6
Mean±SE.
All analyses were adjusted for the baseline score.
p Values refer to subcategories that predicted changes in the Seattle Angina Questionnaire at 6 months. The magnitude of changes across individual variables are given where p≤0.15.
*Within 6 months of randomisation.
CTCA, CT coronary angiography.
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angina due to coronary heart disease was refuted by the CTCA,
most improvements were seen in those where CTCA demon-
strated normal (22±2.3, p<0.001) or mild (22±3.9, p<0.001)
coronary artery disease. In contrast, where a baseline diagnosis
of angina due to coronary heart disease was not thought to be
present but was subsequently corrected to conﬁrm its presence
by the CTCA, symptoms improved most if patients were found
to have obstructive two-vessel or three-vessel disease (18±5.2
and 20±7.3, respectively).
Treatment satisfaction was excellent at baseline and fell
slightly across all groups. However, it fell less in those aged 60–
75 years (−4±0.6) than those aged 18–59 years (−6±0.6).
Other predictors of a lower decline in treatment satisfaction
included a normal exercise ECG (−4±0.6 vs −6±1.1), undergo-
ing coronary revascularisation (−3±1.3 vs −5±0.4) and cancel-
lation of preventative therapies (−2±2.2 vs −5±0.5 (no change)
and −7±1.1 (new therapy initiated)).
Improvements in quality of life were predicted by a number
of factors. Predictors of reduced improvements in quality of life
included history of coronary heart disease (10±1.7 vs 16±0.6),
post-CTCA diagnosis of coronary heart disease (three-vessel
coronary heart disease (11±2.0) and moderate non-obstructive
coronary heart disease (11±1.3) compared with normal (20
±0.9) or single-vessel coronary heart disease (15±1.6)) and
exercise ECG (abnormal (15±1.4), inconclusive (13±1.5) or
not performed (12±1.5) compared with normal (17±0.7)).
Interestingly, cancellation of preventative therapy was associated
with the most improvement in quality of life (26±2.7)
compared with no change (16±0.6) or initiation of new therapy
(12±1.4).
DISCUSSION
In patients with suspected angina due to coronary heart disease,
attendance at the cardiology outpatient clinic is associated with
high levels of immediate treatment satisfaction and symptomatic
improvement. While markedly clarifying the diagnosis for the
attending clinician, CTCA was associated with a small attenu-
ation of improvements in overall symptoms and quality of life
compared with standard care alone. Poorer symptom outcomes
appeared to be attributable to changes in the diagnosis and espe-
cially the detection of moderate non-obstructive coronary artery
disease. However, the greatest improvements in symptoms were
seen in those with normal exercise tolerance, normal coronary
arteries and those who had preventative therapies cancelled.
Previous head-to-head comparisons of CTCA with exercise
stress testing have demonstrated either neutral ﬁndings or
improved symptoms and quality of life immediately after investi-
gation.8 9 Indeed, many studies have suggested a high degree of
short-term patient satisfaction and preference for CTCA.10–13
Here, we have investigated the additional effect of CTCA on
the improvements in patients’ symptoms following attendance at
the rapid access chest pain clinic that included an exercise test in
the majority (85%) of attendances. We have made a number of
notable and novel observations, some of which may initially
seem counterintuitive. How can CTCA attenuate the 6-month
improvement in symptoms when it clariﬁes the diagnosis,
enhances the appropriate use of invasive coronary angiography,
alters preventative and anti-anginal treatments, and reduces the
incidence of myocardial infarction?1 2 14
It should be remembered that two-thirds of patients who
attended the cardiology clinic with chest pain were not diag-
nosed with angina pectoris due to coronary heart disease.
Moreover, CTCA increased the diagnosis of coronary heart
disease but decreased the diagnosis of angina due to coronary
heart disease. Patients diagnosed with non-cardiac chest pain
have higher levels of anxiety than those diagnosed with cardiac
pain since their symptoms are perceived to be less controllable
or understandable.15 For these patients, the outcome of a CTCA
will commonly include a diagnosis of covert non-obstructive
coronary heart disease with the consequence that patients may
become more confused and concerned about their future health
and well-being. This would also explain the association of
reduced improvements in quality of life with the new prescrip-
tion of preventative therapies. It is therefore perhaps not unsur-
prising that CTCA was associated with worse symptomatic
outcomes for such patients. Intriguingly, patients with moderate
non-obstructive coronary artery disease had the worst symptom-
atic outcomes across all ﬁve domains of the Seattle Angina
Questionnaire, even in comparison to patients with obstructive
triple-vessel coronary heart disease. Ultimately for these
patients, CTCA did not provide the reassurance they were
looking for nor did it identify the cause of their presenting
symptoms of chest pain.
For some patients, CTCA was associated with better symp-
tomatic outcomes. This predominantly related to patients who
had an initial clinic diagnosis of angina pectoris due to coronary
heart disease where the CTCA was able to demonstrate the
absence of coronary heart disease. This led to the cancellation
of unnecessary anti-anginal and preventative therapies, and was
associated with the better improvements in symptoms and
quality of life. In addition, it is important to recognise that
despite high levels of treatment satisfaction the majority of
patients who are diagnosed with non-cardiac chest pain con-
tinue to be concerned that there is an underlying cardiac cause
of their chest pain.3 The documentation of normal coronary
arteries by CTCA was associated with the greatest improvements
in symptoms and quality of life, suggesting that CTCA may be
particularly valuable to provide reassurance for patients who
remain anxious about the possibility of covert coronary heart
disease. Of course, should the CTCA demonstrate non-
obstructive coronary heart disease, this will only serve to
increase their anxiety.
Which patients should we select for CTCA to improve symp-
toms? We explored the determinants of symptomatic improve-
ments in patients undergoing CTCA. Perhaps unsurprisingly and
consistent with previous studies,16 those with the worst symp-
toms derived most beneﬁt from clinic attendance and investiga-
tion. Beyond this, important predictors included the absence of
a history of coronary heart disease, normal exercise tolerance
testing, normal coronary arteries on CTCA, undergoing coron-
ary revascularisation and cancellation of preventative therapies.
This would therefore suggest that the major symptomatic
beneﬁt of CTCA is in the demonstration of normal coronary
arteries in those who are being treated with inappropriate pre-
ventative therapies, have good exercise tolerance and do not
have known coronary heart disease. This is in keeping with the
current National Institute for Health and Care Excellence guide-
lines on the management of chest pain of recent onset.17
Much like the diagnosis of cancer, the new diagnosis of cor-
onary heart disease, a potentially life-threatening condition, is
unlikely to improve quality of life.18 The increased diagnosis of
non-obstructive coronary heart disease by CTCA is the main
driver for the attenuation of symptomatic improvement in
patients presenting to the cardiology clinic. This is however
counterbalanced by the enhanced improvement in symptoms for
those patients with normal coronary arteries who are taking
unnecessary preventative therapies, as well as the more appro-
priate use of invasive coronary angiography, secondary
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prevention and coronary revascularisation in those with unrec-
ognised obstructive coronary heart disease.2 Ultimately, it is
important to balance the small increase in anxiety caused by the
identiﬁcation of covert coronary artery disease, and the major
beneﬁts of initiating appropriate symptomatic and preventative
therapy to avoid future cardiac events given the reduction in
overall rates of subsequent myocardial infarction.1 2 14
We acknowledge that the magnitude of the differences
between the study groups are small and often less than ﬁve
points of a 100-point scale. However, these are population dif-
ferences and such small changes can be important. For example,
while a 2–4 mm Hg fall in blood pressure is very small on an
individual level, this is associated with 28% reduction in the
rate of stroke and 22% reduction in death at a population
level.19 Furthermore, consistent with the heterogeneous proﬁle
of the study population, we found more marked differences
within different groups especially with respect to the extent of
coronary artery disease. This is perhaps not unsurprising given
that CTCA deﬁnes this aspect of the patient’s proﬁle and
increased the diagnosis of coronary heart disease.
We should acknowledge some limitations of our study. We do
not have information on the psychological status of our patients
nor do we have detailed information on coronary microvascular
function. Some of the participants may have had angina due to
coronary microvascular disease, and this can affect 10–30% of
patients with angina and non-obstructive coronary heart
disease20 21 and cessation of angina therapy may have led to a
deterioration in symptoms. We also cannot discount misclassiﬁ-
cation of disease. CTCA provides a non-invasive imaging assess-
ment of the anatomical severity of coronary artery disease and
is less accurate than invasive angiography with quantitative ana-
lysis or functional techniques, such as fractional ﬂow reserve.
However, it is reassuring that in patients who underwent CTCA
the frequency of normal coronary angiography was reduced by
two-thirds and obstructive disease was substantially more
common at the time of invasive angiography.2
In conclusion, CTCA attenuates the overall improvement in
symptoms of patients presenting with suspected angina pectoris
due to the increased diagnosis of coronary heart disease. CTCA
is associated with better symptomatic outcomes in patients
proven to have normal coronary arteries who had preventative
therapies cancelled, while poorer symptom outcomes were seen
for those with undiagnosed non-obstructive coronary heart
disease for whom preventative therapies were initiated. These
effects on symptoms need to be balanced against the potential
beneﬁts of improved focused clinical management and reduc-
tions in the rates of myocardial infarction.1 2 14
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Key messages
What is already known on this subject?
Previous head-to-head comparisons of CT coronary angiography
(CTCA) with exercise stress testing have demonstrated either
neutral ﬁndings or improved symptoms and quality of life
immediately after investigation. Indeed, many studies have
suggested a high degree of short-term patient satisfaction and
preference for CTCA.
What might this study add?
CTCA is associated with a small attenuation of the
improvements in overall symptoms and quality of life compared
with standard care alone. This appears to be attributable to
changes in the diagnosis and especially the detection of
moderate non-obstructive coronary artery disease. The greatest
improvements in symptoms are seen in those with normal
exercise tolerance, normal coronary arteries and those who have
preventative therapies cancelled.
How might this impact on clinical practice?
CTCA improves symptoms by identifying patients with normal or
obstructive coronary heart disease. In untreated patients with
atypical symptoms, clinicians need to discuss the implications of
potential CTCA ﬁndings including non-obstructive disease that
would mandate preventative therapies to avoid future coronary
heart disease events.
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